ACE-031 is a recombinant fusion protein originally developed by Acceleron Pharma (now Merck) as a clinical candidate for Duchenne muscular dystrophy (DMD) and muscle-wasting conditions. It acts as a high-affinity decoy receptor that sequesters myostatin (GDF-8), activin A, and other TGF-β family ligands, preventing them from binding endogenous ActRIIB receptors and thereby releasing inhibition of muscle growth. Phase 2 trials demonstrated significant lean mass gains (+3–5% in healthy adults) and strength improvements, but development was halted due to minor epistaxis/telangiectasia side effects. This research-grade lyophilized protein is produced under strict quality controls and provided with full analytical documentation, making it the gold-standard tool for myostatin inhibition and muscle regeneration research.
Key Scientific
- High-purity ACE-031 (≥ 98% by HPLC/SEC, recombinant human sequence)
- Verified ActRIIB extracellular domain + IgG1-Fc fusion with correct disulfide bonding
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, SEC, binding ELISA (myostatin/activin A), and endotoxin testing
- Manufactured in GMP-aligned, ISO-compliant facilities
- Ideal for myostatin blockade, muscle hypertrophy, and neuromuscular disease models
Research-Referenced Attributes (Based on scientific literature & clinical trials; not therapeutic claims.)
- Potent myostatin/activin A trap → dose-dependent muscle hypertrophy (up to +12% in preclinical models)
- Phase 2 trial (healthy postmenopausal women): 1–3 mg/kg every 4 weeks → +3.1–5.2% lean mass, +30% thigh muscle volume
- Increases strength and functional performance in DMD mouse models (mdx)
- Improves bone density and fat metabolism secondary to muscle growth
- Well-characterized safety profile from human trials (minor nosebleeds/telangiectasias at high doses)
- Valuable in sarcopenia, cachexia, DMD, and performance physiology research
Why Researchers Choose Nationwide Peptides ACE-031
- Exact clinical-sequence match to Acceleron’s Phase 2 candidate
- Highest documented myostatin-binding affinity among research suppliers
- Transparent analytical data (HPLC/SEC >98%, functional binding ELISA)
- Trusted by muscle physiology, neuromuscular disease, and regenerative medicine laboratories
- Competitive research pricing with bulk options
